AMC momentum traders have lost strength and they know AMC will drop hard this time. If there is a short squeeze, it will be limited. There is any potential good news to support. I won't be surprised it drops below $20 in the next few days. Good time to trade on options.$AMC Entertainment(AMC)$

 SoFi’s total membership gained 113% year-over-year to 2.6 million, up from 1.2 million at the same point last year. And total products rose 123% to 3.7 million at quarter-end compared to 1.6 million at the same point last year.$SoFi Technologies Inc.(SOFI)$

Just avoid Singapore's DBS.  Refused to invest in banks. The source of evil where rich gets richer and poor ...was supposed to help the poor $DBS GROUP HOLDINGS LTD(D05.SI)$

Just checked Shortvolumes. MASSIVE shorting yesterday too, with almost 55% shorting. Despite huge fees and a looming FDA approval right around the corner. Hope you are ready shorts, we are gonna squeeze the living #$%$ out of you in our GLORIOUS trip to Saturn ???$Orphazyme A/S(ORPH)$

$纳斯达克100指数(NDX)$ $标普500(.SPX)$ Often asked, the most reliable indicator there is, is not an indicator, it's price. A price trend of higher highs and higher lows is an uptrend. Until it starts making lower highs and lower lows, for your time frame, it's an uptrend. $SPX $NDX

every time we think this pig is breaking out it falls on it’s face flat. another-5% kind of day today$Palantir Technologies Inc.(PLTR)$

Wall Street leeches got their feelings hurt when AMD obliterated the market value of $NVDA and $INTC. Warren Buffett never invested in tech because newer better technology can replace your product in the blink of an eye. He broke his rule and invested in $AAPL. He'll be sorry.$Apple(AAPL)$ $NVIDIA Corp(NVDA)$ $Intel(INTC)$

$Orphazyme A/S (ORPH)$ is looking good. Nice and steady. Big potential upswing just around the corner with the next updated by Orphazyme. Just imagine how the management team feels like right now. I bet they are doing everything they can to not only get their European approval, but also start a dialogue with FDA in the light of their recent 36 month data.